1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Siegfried Holding AG
  6. News
  7. Summary
    SFZN   CH0014284498

SIEGFRIED HOLDING AG

(SFZN)
  Report
Delayed Swiss Exchange  -  11:31 2022-07-05 am EDT
653.00 CHF   +2.11%
06/30SIEGFRIED HOLDING AG : Capital return instalment
FA
04/28Sanofi profit gain beats market view on bestseller drug Dupixent
RE
04/13SIEGFRIED : Increases Distribution and Appoints Two New Board Members
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Siegfried : and BioNTech Sign Contract for the Aseptic Fill & Finish of a COVID-19 Vaccine

09/14/2020 | 12:20pm EDT

The Siegfried Group (SIX: SFZN) announces that it has signed a cooperation and supply agreement with Biopharmaceutical New Technologies (BioNTech), a German immunotherapy company, for the large-scale filling and packaging of commercial quantities of BNT162b2, an innovative COVID-19 vaccine candidate. Following successful approval, the vaccine developed by BioNTech in cooperation with Pfizer, a US American pharmaceutical company, will be filled by Siegfried at its Hameln site from mid 2021 onwards.

Siegfried CEO Dr. Wolfgang Wienand: 'We are proud to make an important contribution toward combatting the pandemic through this partnership, and we are determined to support BioNTech in the best possible way. As a leading CDMO company with a strong global manufacturing network, Siegfried is in a position to take on technologically demanding tasks at short notice and to quickly build up the necessary capacities.'

The BNT162b2 vaccination, jointly developed by BioNTech and Pfizer, is currently undergoing global pivotal clinical phase 2/3 trials. If the study is successful, it is planned to seek regulatory review in October 2020. For the aseptic filling and packaging ('fill & finish') of the vaccine, Siegfried will invest in a dedicated production line at its Hameln (Germany) site and provide special storage capacity. The first phase of the agreement will end 2022, with the shared intention to expand the cooperation into a strategic partnership between BioNTech and Siegfried.

Marianne Späne, Global Head Business Development & Sales at Siegfried: 'We very much look forward toward the cooperation with this pioneer company for biopharmaceuticals. This contract, for which we will make full use of our technical capabilities and high quality standards, represents the first step for us toward a long-term partnership with further potential.'

» Media Relase (PDF)

Contact Media:
Peter Gehler, Chief Communications Officer
peter.gehler@siegfried.ch
Tel. +41 62 746 11 48
Mob. +41 79 416 41 16

Contact Financial Analysts:
Reto Suter, Chief Financial Officer
reto.suter@siegfried.ch
Tel. +41 62 746 11 35

Siegfried Holding AG
Untere Bruehlstrasse 4
CH-4800 Zofingen
Tel. +41 62 746 11 11


About Siegfried
The Siegfried Group is a global life sciences company with sites in Switzerland, the USA, Malta, China, Germany and France. In 2019, the company achieved sales of 833.5 million Swiss francs and currently employs about 2500 people at nine sites on three continents. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN).

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, and cartridges) for the pharmaceutical industry and provides development services.

Disclaimer

Siegfried Holding AG published this content on 14 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 September 2020 16:19:04 UTC


© Publicnow 2020
All news about SIEGFRIED HOLDING AG
06/30SIEGFRIED HOLDING AG : Capital return instalment
FA
04/28Sanofi profit gain beats market view on bestseller drug Dupixent
RE
04/13SIEGFRIED : Increases Distribution and Appoints Two New Board Members
PU
04/01Sanofi to float drug ingredients manufacturing business on May 6
RE
03/04BNP Paribas Lowers Price Target on Siegfried, Maintains Outperform Recommendation
MT
02/25Siegfried Holding AG Reports Earnings Results for the Full Year Ended December 31, 2021
CI
02/25Mirabaud Securities Lifts Price Target on Siegfried, Upgrades Recommendation to Buy
MT
02/23SIEGFRIED : For the first time, Siegfried reports sales of more than one billion Swiss fra..
PU
02/23Siegfried's FY21 Profit Climbs After Sales Exceed $1 Billion Mark; Board Ups Dividend
MT
02/23TRANSCRIPT : Siegfried Holding AG, 2021 Earnings Call, Feb 23, 2022
CI
More news
Analyst Recommendations on SIEGFRIED HOLDING AG
More recommendations
Financials
Sales 2022 1 228 M 1 267 M 1 267 M
Net income 2022 123 M 127 M 127 M
Net Debt 2022 445 M 459 M 459 M
P/E ratio 2022 22,9x
Yield 2022 0,52%
Capitalization 2 773 M 2 861 M 2 861 M
EV / Sales 2022 2,62x
EV / Sales 2023 2,48x
Nbr of Employees 3 488
Free-Float 88,3%
Chart SIEGFRIED HOLDING AG
Duration : Period :
Siegfried Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SIEGFRIED HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 653,00 CHF
Average target price 905,78 CHF
Spread / Average Target 38,7%
EPS Revisions
Managers and Directors
Wolfgang Wienand Chief Executive Officer
Reto Suter Chief Financial Officer
Andreas Casutt Chairman
Jürgen Roos Chief Scientific Officer
Reto A. Garzetti Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SIEGFRIED HOLDING AG-28.11%2 825
JOHNSON & JOHNSON4.94%472 389
PFIZER, INC.-11.41%293 506
ELI LILLY AND COMPANY18.45%292 291
ROCHE HOLDING AG-14.90%274 360
ABBVIE INC.13.59%271 782